Trial Profile
A Multi-Center Observational Survey of Breast Cancer Patients With Metastatic Bone Disease Receiving Oral Ibandronate (BONDORAL)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Aug 2015
Price :
$35
*
At a glance
- Drugs Ibandronic acid (Primary)
- Indications Bone metastases
- Focus Therapeutic Use
- Acronyms BONDORAL
- Sponsors Roche
- 21 Aug 2015 New trial record